Cargando…

Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology

PURPOSE: Emerging evidence suggests G3 pancreatic neuroendocrine neoplasms (pNENs) present heterogeneous morphology and biology. The 2017 WHO classification has introduced a new category of well-differentiated pancreatic neuroendocrine tumors (WD-pNETs) G3, compared with poorly differentiated pancre...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xu, Xu, Xuefeng, Ma, Hongyun, Ji, Yuan, Wang, Dansong, Kuang, Tiantao, Wu, Wenchuan, Song, Bin, Li, Gang, Jin, Gang, Lou, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825924/
https://www.ncbi.nlm.nih.gov/pubmed/29472376
http://dx.doi.org/10.1530/EC-17-0388
_version_ 1783302256709337088
author Han, Xu
Xu, Xuefeng
Ma, Hongyun
Ji, Yuan
Wang, Dansong
Kuang, Tiantao
Wu, Wenchuan
Song, Bin
Li, Gang
Jin, Gang
Lou, Wenhui
author_facet Han, Xu
Xu, Xuefeng
Ma, Hongyun
Ji, Yuan
Wang, Dansong
Kuang, Tiantao
Wu, Wenchuan
Song, Bin
Li, Gang
Jin, Gang
Lou, Wenhui
author_sort Han, Xu
collection PubMed
description PURPOSE: Emerging evidence suggests G3 pancreatic neuroendocrine neoplasms (pNENs) present heterogeneous morphology and biology. The 2017 WHO classification has introduced a new category of well-differentiated pancreatic neuroendocrine tumors (WD-pNETs) G3, compared with poorly differentiated pancreatic neuroendocrine carcinomas (PD-pNECs) G3. We aim to analysis the demographics and outcomes of patients with resectable 2017 WHO G3 pNENs to facilitate the distinction between two entities. METHODS: The multi-institutional retrospective cohort involving 57 surgically treated patients affected by 2017 WHO G3 pNENs were morphologically identified and clinically analyzed. Patients having WD-pNETs G3 and those having PD-pNECs G3 were compared. RESULTS: Thirty patients had WD-pNETs and 27 patients had PD-pNECs. The distributions of Ki-67 and mitotic count in patients with PD-pNECs or WD-pNETs showed remarkable disparities. ROC indicated cut-off value of Ki-67 was 45. PD-pNECs were more common in patients with elevated Ki-67 and mitotic count, advanced AJCC TNM stage, vascular invasion, regional lymph-node metastases, elevated NSE and decreased CgA levels compared with WD-pNETs (P < 0.05). The association between 2017 WHO G3 grade and TTR was statistically significant (P < 0.05). Univariate analysis indicated OS rates were associated with morphologic differentiation (WD-pNETs vs PD-pNECs), Ki-67, TNM staging, synchronous distant metastases, initial treatments, vascular invasion, regional lymph nodes metastases, mitotic count and age (P < 0.05). Multivariate analyses illustrated Ki-67, differentiation, TNM staging and vascular invasion were independent predictors (P < 0.05). CONCLUSIONS: PD-pNECs G3 presented malignant biological behavior and dismal outcome compared with WD-pNETs G3. These findings challenge 2010 WHO classification and suggest the categorization can be improved by refined tumor grading.
format Online
Article
Text
id pubmed-5825924
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-58259242018-03-01 Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology Han, Xu Xu, Xuefeng Ma, Hongyun Ji, Yuan Wang, Dansong Kuang, Tiantao Wu, Wenchuan Song, Bin Li, Gang Jin, Gang Lou, Wenhui Endocr Connect Research PURPOSE: Emerging evidence suggests G3 pancreatic neuroendocrine neoplasms (pNENs) present heterogeneous morphology and biology. The 2017 WHO classification has introduced a new category of well-differentiated pancreatic neuroendocrine tumors (WD-pNETs) G3, compared with poorly differentiated pancreatic neuroendocrine carcinomas (PD-pNECs) G3. We aim to analysis the demographics and outcomes of patients with resectable 2017 WHO G3 pNENs to facilitate the distinction between two entities. METHODS: The multi-institutional retrospective cohort involving 57 surgically treated patients affected by 2017 WHO G3 pNENs were morphologically identified and clinically analyzed. Patients having WD-pNETs G3 and those having PD-pNECs G3 were compared. RESULTS: Thirty patients had WD-pNETs and 27 patients had PD-pNECs. The distributions of Ki-67 and mitotic count in patients with PD-pNECs or WD-pNETs showed remarkable disparities. ROC indicated cut-off value of Ki-67 was 45. PD-pNECs were more common in patients with elevated Ki-67 and mitotic count, advanced AJCC TNM stage, vascular invasion, regional lymph-node metastases, elevated NSE and decreased CgA levels compared with WD-pNETs (P < 0.05). The association between 2017 WHO G3 grade and TTR was statistically significant (P < 0.05). Univariate analysis indicated OS rates were associated with morphologic differentiation (WD-pNETs vs PD-pNECs), Ki-67, TNM staging, synchronous distant metastases, initial treatments, vascular invasion, regional lymph nodes metastases, mitotic count and age (P < 0.05). Multivariate analyses illustrated Ki-67, differentiation, TNM staging and vascular invasion were independent predictors (P < 0.05). CONCLUSIONS: PD-pNECs G3 presented malignant biological behavior and dismal outcome compared with WD-pNETs G3. These findings challenge 2010 WHO classification and suggest the categorization can be improved by refined tumor grading. Bioscientifica Ltd 2018-01-30 /pmc/articles/PMC5825924/ /pubmed/29472376 http://dx.doi.org/10.1530/EC-17-0388 Text en © 2018 The authors http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Han, Xu
Xu, Xuefeng
Ma, Hongyun
Ji, Yuan
Wang, Dansong
Kuang, Tiantao
Wu, Wenchuan
Song, Bin
Li, Gang
Jin, Gang
Lou, Wenhui
Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
title Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
title_full Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
title_fullStr Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
title_full_unstemmed Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
title_short Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
title_sort clinical relevance of different who grade 3 pancreatic neuroendocrine neoplasms based on morphology
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825924/
https://www.ncbi.nlm.nih.gov/pubmed/29472376
http://dx.doi.org/10.1530/EC-17-0388
work_keys_str_mv AT hanxu clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT xuxuefeng clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT mahongyun clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT jiyuan clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT wangdansong clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT kuangtiantao clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT wuwenchuan clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT songbin clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT ligang clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT jingang clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology
AT louwenhui clinicalrelevanceofdifferentwhograde3pancreaticneuroendocrineneoplasmsbasedonmorphology